TABLE 1.
Characteristics of Studies Included in the Meta-analysis
| Study | Study Design | Country | Year | Development Scale | Quality | ARV | Domain | mHIV+ | seHIV+ | mHEU | seHEU | mHUU | seHUU | nHIV+ | nHEU | nHUU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chase et al16 | L | United States | 1995 | BSID-I | HQ | Child | MDI | 83.1 | 16.1 | 94.8 | 18.2 | — | — | 24 | 27 | — |
| PDI | 85.8 | 16.4 | 97.8 | 16.7 | — | — | 24 | 27 | — | |||||||
| Chase et al25 | L | United States | 2000 | BSID-I | HQ | Child | MDI | 83.1 | 23.0 | 94.4 | 16.1 | — | — | 57 | 220 | — |
| PDI | 83.5 | 23.8 | 101.2 | 16.8 | — | — | 57 | 213 | — | |||||||
| Gómez et al26 | L | Colombia | 2009 | BSID-II | LQ | Mother | MDI | — | — | 83 | 10.3 | 99 | 12.3 | — | 15 | 15 |
| PDI | — | — | 98 | 13.5 | 103 | 12.3 | — | 15 | 15 | |||||||
| Hutchings and Potterton18 | CS | Zimbabwe | 2014 | BSID-III | LQ | Both | MDI | 75.89 | 17.69 | 100.31 | 12.75 | — | — | 28 | 32 | — |
| PDI | 79.71 | 20.91 | 106.16 | 10.20 | — | — | 28 | 32 | — | |||||||
| Knight et al27 | L | United States | 2000 | BSID-I | HQ | None | MDI | 73.2 | 30.5 | 86.4 | 18.4 | — | — | 20 | 25 | — |
| PDI | 80.6 | 28.2 | 98.3 | 24.1 | — | — | 20 | 25 | — | |||||||
| Lindsey et al19 | L | United States | 2007 | BSID-I | HQ | Both | MDI | 85 | 22 | 105 | 17 | — | — | 54 | 221 | — |
| PDI | 77 | 25 | 107 | 16 | — | — | 54 | 221 | — | |||||||
| Lindsey et al19 | L | United States | 2007 | BSID-II | HQ | Both | MDI | 75 | 17 | 79 | 17 | — | — | 47 | 350 | — |
| PDI | 84 | 17 | 87 | 17 | — | — | 47 | 349 | — | |||||||
| McDonald et al29 | L | Tanzania | 2013 | BSID-II | LQ | None | MDI | 81.6 | 13.7 | 87 | 11.4 | — | — | 25 | 90 | — |
| PDI | 80.4 | 16.2 | 88.9 | 16.8 | — | — | 25 | 90 | — | |||||||
| Mellins et al7 | CS | United States | 1994 | BSID-I | HQ | None | MDI | 75.50 | 29.00 | 85.03 | 22.03 | 83.83 | 17.48 | 24 | 30 | 23 |
| PDI | 73.58 | 29.35 | 90.01 | 20.06 | 89.83 | 11.70 | 24 | 30 | 23 | |||||||
| Peterson et al28 | CS | Uganda | 2001 | BSID-I | LQ | None | MDI | 79.3 | 18.0 | 91.6 | 13.1 | 91.6 | 13.1 | 10 | 25 | 25 |
| PDI | 79.0 | 20.7 | 94.1 | 16.8 | 94.1 | 16.8 | 10 | 25 | 25 | |||||||
| Van Rie et al24 | L | DRC | 2009 | BSID-I | LQ | Child | MDI | 84.3 | 21.73 | 87.6 | 19.92 | 96.5 | 24.2 | 35 | 35 | 90 |
| PDI | 90.4 | 11.47 | 94.0 | 10.87 | 105.0 | 12.6 | 35 | 35 | 90 | |||||||
| Whitehead et al22 | L | South Africa | 2014 | BSID-III | LQ | Child | MDI | 94.75 | 14.09 | 98.95 | 10.61 | — | — | 20 | 19 | — |
| PDI | 93.7 | 10.89 | 105.58 | 10.88 | — | — | 20 | 19 | — |
ARV, antiretroviral medication exposure; CS, cross-sectional; DRC, Democratic Republic of Congo; HQ, high quality; L, longitudinal; LQ, low quality; mHEU, mean score for HIV-exposed but uninfected; mHIV+, mean score for HIV-infected; mHUU, mean score for HIV-unexposed and uninfected; nHEU, number of HIV-exposed but uninfected children included in the analyzed sample; nHIV+, number of HIV-infected children included in the analyzed sample; nHUU, number of HIV-unexposed and uninfected children included in the analyzed sample; seHEU, SE for HIV-exposed but uninfected; seHIV+, SE for HIV-infected; seHUU, SE for HIV-unexposed and uninfected; —, not applicable.